Everything You Need to Know About Tresiba Prescribing Information
Diabetes is a chronic disease that affects millions of people worldwide. Fortunately, medication such as Tresiba can help manage diabetes and maintain a healthy lifestyle. As a healthcare provider, it’s crucial to understand the prescribing information for Tresiba to ensure safe and effective treatment.
What is Tresiba?
Tresiba is a long-acting insulin analog that controls blood glucose levels in people with diabetes. It is administered as an injection via subcutaneous mode. Tresiba’s active ingredient is insulin degludec, which has a longer half-life than other insulin analogs, about 25 hours.
Who can use Tresiba?
Tresiba is approved for adults with diabetes, including type 1 and type 2. It can also be used in children aged one year and above with type 1 diabetes. However, Tresiba isn’t recommended for people with diabetic ketoacidosis or those who have a known hypersensitivity to insulin degludec.
How is Tresiba dosed?
The dosage of Tresiba is individualized based on the patient’s metabolic needs, blood glucose monitoring, and glycemic control goal. The starting dose for Tresiba in patients with type 1 diabetes is 0.2 to 0.4 units/kg/day. Meanwhile, patients with type 2 diabetes and those switching from basal insulin to Tresiba usually start at a dose of 10 units/day.
What are the common side effects of Tresiba?
Tresiba generally has a favorable safety profile. However, some patients may experience side effects such as hypoglycemia, injection site reactions, and weight gain. Hypoglycemia is an adverse event that can occur if the dose of Tresiba is too high. Injection site reactions include pain, swelling, and redness that usually resolve over time. Weight gain can occur due to insulin therapy, and patients need to monitor their diet and exercise regularly to maintain an ideal weight.
What should healthcare providers know about Tresiba?
Healthcare providers should be familiar with the prescribing information for Tresiba, which includes dosing guidelines, contraindications, warnings, and precautions. They should also educate patients on how to self-administer Tresiba, monitor blood glucose levels regularly, and adjust the dose as necessary. Additionally, healthcare providers should be prepared to manage adverse reactions such as hypoglycemia and injection site reactions.
Conclusion
Tresiba is a valuable treatment option for managing diabetes in adults and children. However, healthcare providers should be aware of the prescribing information for Tresiba to ensure safe and effective therapy. By understanding the appropriate dosing, potential side effects, and patient monitoring, healthcare providers can develop a comprehensive treatment plan that improves the patient’s quality of life.
